Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Syncona Shs GBP ( (GB:SYNC) ) just unveiled an update.
iOnctura, a company in Syncona’s portfolio, announced promising results from its Phase I DIONE-01 study of roginolisib, an allosteric modulator of PI3K delta, for treating uveal melanoma. The study demonstrated the drug’s safety and efficacy, with patients showing a doubling of overall survival compared to historical controls. These results pave the way for the Phase II OCULE-01 study, which could significantly impact iOnctura’s market position and Syncona’s investment value in cancer therapies.
More about Syncona Shs GBP
Syncona Limited is a leading life science investor focused on developing transformative treatments in areas with high unmet medical needs. It aims to build globally leading life science companies by investing in a diversified portfolio of 20-25 businesses, spanning various development stages, modalities, and therapeutic areas. The company collaborates with world-class academic founders and experienced management teams to enhance human life by delivering impactful patient treatments.
YTD Price Performance: -17.34%
Average Trading Volume: 784,265
Technical Sentiment Consensus Rating: Buy
For detailed information about SYNC stock, go to TipRanks’ Stock Analysis page.
